d9780581-dfca-4e83-9bb4-4836f22d910e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- INTERFERON_ALPHA_RESPONSE+0.510
- OXIDATIVE_PHOSPHORYLATION+0.500
- MYC_TARGETS_V1+0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- INTERFERON_GAMMA_RESPONSE+0.410
- MTORC1_SIGNALING+0.410
- TNFA_SIGNALING_VIA_NFKB+0.360
- ALLOGRAFT_REJECTION+0.310
- UV_RESPONSE_UP+0.290
Top 10 suppressed
- BILE_ACID_METABOLISM-0.350
- PROTEIN_SECRETION-0.320
- UV_RESPONSE_DN-0.280
- MITOTIC_SPINDLE-0.170
- WNT_BETA_CATENIN_SIGNALING-0.170
- HEME_METABOLISM-0.160
- TGF_BETA_SIGNALING-0.150
- ANDROGEN_RESPONSE-0.110
- APICAL_SURFACE-0.110
- HEDGEHOG_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-A6UO-01A-12R-A34R-07 | — | — | 0.829 |
| 2 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.825 |
| 3 | TCGA-XF-A9T5-01A-11R-A42T-07 | — | — | 0.824 |
| 4 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.823 |
| 5 | DRR168607 | — | — | 0.821 |
| 6 | SRR8518265 | — | E | 0.820 |
| 7 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.820 |
| 8 | MNG742 | — | — | 0.817 |
| 9 | MNG1266 | — | — | 0.811 |
| 10 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |